Skip to main content
Parker Cancer ends here
Research Update

Cancer Vaccines: A New Era in Cancer Treatment

June 4, 2026
Cancer Vaccines: A New Era in Cancer Treatment

The Parker Institute for Cancer Immunotherapy (PICI) is a leader in one of the most exciting frontiers  in cancer research: therapeutic cancer vaccines.These vaccines are designed to help the immune system recognize, attack, and remember cancer cells—offering the potential for more precise, durable, and less toxic treatment.Recent clinical results have generated extraordinary excitement throughout the scientific community and hope for patients and families facing cancer.By bringing together leading cancer researchers and institutions under a single umbrella,  PICI is uniquely poised to accelerate the development of therapies that could transform cancer care.The goal is ambitious, but increasingly within reach: With cancer vaccines and immunotherapy working for more patients and more cancers, we aim to make ALL cancers curable diseases.

FAQ

Not What You Might ThinkWhen people hear the word "vaccine," they often think about preventing infectious diseases like measles or the flu.Cancer vaccines are different.Most therapeutic cancer vaccines are designed for people who already have cancer or who are at high risk of cancer returning after treatment.Cancer has traditionally been difficult to treat because it originates from a person's own cells, making it harder for the immune system to recognize it as a threat.So, think of a cancer vaccine as a “wanted poster” for your immune system.Scientists can now analyze a patient's tumor, identify unique markers found only on the cancer cells and then use a vaccine to teach your immune system to recognize and destroy cancer cells with greater precision. Cancer vaccines have already demonstrated the ability to safely generate powerful immune responses in multiple cancer types including glioblastoma, breast, pancreatic, kidney, lung and others. Researchers are now working to translate those immune responses into long-term clinical benefit for more patients.The ultimate goal is to create a durable immune response that continues protecting patients long after treatment has ended.